Clinical Report: Effectiveness and Safety of Goserelin Microspheres vs Implants

Overview

This study evaluates the effectiveness and safety of goserelin sustained-release microspheres compared to implants in prostate cancer patients. Results indicate comparable biochemical activity and safety profiles between the two formulations over a 12-week period.

Background

Prostate cancer is a significant health concern, particularly in older men, and androgen deprivation therapy (ADT) is a cornerstone of treatment. Goserelin, a GnRH agonist, is available in two formulations, and understanding their comparative effectiveness and safety is crucial for optimizing patient care in clinical practice.

Data Highlights

Key Findings

• At day 29, TPSA response rates were 81.8% for microspheres and 95.2% for implants.
• At day 85, TPSA response rates were 86.4% for microspheres and 93.0% for implants.
• The study met the prespecified non-inferiority criterion for goserelin microspheres.
• Pooled incidence of any-grade adverse events was 59.2% across included studies.
• No new safety signals were identified for either formulation.
• Baseline disease stage differed, with more metastatic cases in the implant group.

Clinical Implications

Goserelin sustained-release microspheres can be considered a viable alternative to implants for ADT in prostate cancer, offering comparable efficacy and safety. Clinicians should be aware of the differences in early PSA response and baseline disease characteristics when selecting treatment options.

Conclusion

Goserelin microspheres demonstrate comparable effectiveness to implants in real-world settings, supporting their use as an alternative formulation in prostate cancer management.

Related Resources & Content

1. Frontiers, Source, 2026 -- Comparative effectiveness and integrated safety of goserelin sustained-release microspheres versus implants in prostate cancer
2. EAU Guidelines, 2026 -- Guidelines on Prostate Cancer
3. NCCN Guidelines, 2026 -- Prostate Cancer
4. The ASCO Post — Long-Term Follow-up of Premenopausal Patients With Estrogen Receptor–Positive Breast Cancer: Goserelin and Tamoxifen
5. The ASCO Post — Testosterone/Anastrozole Implants Relieve Menopausal Symptoms in Breast Cancer Survivors
6. The ASCO Post — Transdermal Estradiol Patches vs LHRH Agonists in Locally Advanced Prostate Cancer
7. The Impact of Gonadotropin-Releasing Hormone Antagonists on Advanced Hormone-Sensitive Prostate Cancer Management in the UK
8. Long-Term Follow-up of Premenopausal Patients With Estrogen Receptor–Positive Breast Cancer: Goserelin and Tamoxifen
9. Testosterone/Anastrozole Implants Relieve Menopausal Symptoms in Breast Cancer Survivors
10. Transdermal Estradiol Patches vs LHRH Agonists in Locally Advanced Prostate Cancer
11. https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-EANM-ESTRO-ESUR-ISUP-SIOG-Guidelines-on-Prostate-Cancer-2026_2026-03-14-104356_ixav.pdf
12. https://www.oregon.gov/oha/HPA/DSI-HERC/MembersOnly/7.8f%20NCCN%202.2026%20prostate.pdf
13. Frontiers | Comparative effectiveness and integrated safety of goserelin sustained-release microspheres versus implants in prostate cancer: a patient-based real-world study and systematic review with meta-analysis
14. Study Details | NCT06385847 | To Assess The Patient Preference for Goserelin Microsphere Versus Goserelin Implant in Patients With Prostate Cancer | ClinicalTrials.gov